Skip to main content

CORRECTION article

Front. Endocrinol., 03 November 2022
Sec. Thyroid Endocrinology
Volume 13 - 2022 | https://doi.org/10.3389/fendo.2022.1073400

Corrigendum: Update on genistein and thyroid: an overall message of safety

Herbert Marini&#x;Herbert Marini1†Francesca Polito&#x;Francesca Polito1†Elena B. Adamo&#x;Elena B. Adamo1†Alessandra BittoAlessandra Bitto2Francesco SquadritoFrancesco Squadrito2Salvatore Benvenga,,*Salvatore Benvenga3,4,5*
  • 1Section of Physiology and Human Nutrition, Department of Biochemical, Physiological and Nutritional Sciences, University of Messina, Messina, Italy
  • 2Section of Pharmacology, Department of Clinical and Experimental Medicine and Pharmacology, University of Messina, Messina, Italy
  • 3Section of Endocrinology, Department of Clinical and Experimental Medicine and Pharmacology, University of Messina, Messina, Italy
  • 4Master on Childhood, Adolescent and Women’s Endocrine Health, University of Messina, Messina, Italy
  • 5Interdepartmental Program of Molecular and Clinical Endocrinology, and Women’s Endocrine Health, University Hospital of Messina, Messina, Italy

A Corrigendum on:
Update on genistein and thyroid: An overall message of safety

by Marini H, Polito F, Adamo EB, Bitto A, Squadrito F and Benvenga S (2012) Front. Endocrin. 3:94. doi: 10.3389/fendo.2012.00094

In the published article, the Conflict of Interest statement was incorrectly filed. The correct Conflict of Interest statement appears below.

Conflict of interest

FS has received research support from Primus Pharmaceuticals for work on genistein. FS and AB are co-inventors on patents referring to genistein activity.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: genistein, isoflavones, soy, safety, thyroid

Citation: Marini H, Polito F, Adamo EB, Bitto A, Squadrito F and Benvenga S (2022) Corrigendum: Update on genistein and thyroid: an overall message of safety. Front. Endocrinol. 13:1073400. doi: 10.3389/fendo.2022.1073400

Received: 18 October 2022; Accepted: 19 October 2022;
Published: 03 November 2022.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2022 Marini, Polito, Adamo, Bitto, Squadrito and Benvenga. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Salvatore Benvenga, s.benvenga@me.nettuno.it

†Herbert Marini, Francesca Polito, and Elena B. Adamo have contributed equally to this work

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.